FMA
GILD icon

FNY Managed Accounts’s Gilead Sciences GILD Stock Holding History

FNY Managed Accounts’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		$6K Buy
+82
New +$6.52K 0.01% 212
2016
Q4 		– Sell
-285
Closed -$1.63K – 126
2016
Q3 		$1.63K Buy
+285
New +$23.2K ﹤0.01% 387

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

FNY Managed Accounts's GILD Position: Q3 2017 in Review

FNY Managed Accounts sold out of Gilead Sciences (GILD) in Q3 2017, closing a stake of 150 shares — an estimated $10K sold.

FNY Managed Accounts first reported a position in GILD in Q1 2014 and held it in 6 quarters. The position peaked at $211K in Q3 2015. 1,503 funds tracked by Wall St. Rank hold GILD as of Q3 2017.

  • FNY Managed Accounts reported no remaining Gilead Sciences position as of Q3 2017 after selling out during the quarter.
  • FNY Managed Accounts sold 150 Gilead Sciences shares in Q3 2017, an estimated $10K.
  • FNY Managed Accounts first reported a position in Gilead Sciences in Q1 2014 and held it in 6 quarters.
  • FNY Managed Accounts's Gilead Sciences position peaked at $211K in Q3 2015.
  • 1,503 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2017.

Based on FNY Managed Accounts's 13F filing for Q3 2017, filed 9 Nov 2017.